MedTrace Logo

Imaging the HIV Reservoir

NCT03063788 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-06-24

No results posted yet for this study

Summary

Radiolabelling broadly neutralizing anti-HIV antibody 3BNC117 with a Copper-64 radio isotope for infusion into people with HIV followed by MRI/PET scanning to detect HIV in vivo.

Conditions

Interventions

DRUG

3BNC117-Copper-64

3 mg/kg 3BNC117 combined with radio-isotope Copper-64

Sponsors & Collaborators

  • The Peter Doherty Institute for Infection and Immunity

    collaborator OTHER

  • Monash University

    collaborator OTHER

  • Monash Health

    collaborator OTHER

  • Rockefeller University

    collaborator OTHER

  • Austin Health

    collaborator OTHER_GOV

  • Bayside Health

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2020-02-01
Completion
2020-04-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03063788 on ClinicalTrials.gov